Ivan Bunganič

Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn’s Disease

Torsten Kucharzik, Rune Wilkens, Maria Antonietta D’Agostino et al. · Clinical Gastroenterology and Hepatology · 2022 · 97 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease

A Tromm, Ivan Bunganič, Eva Tomsová et al. · Gastroenterology · 2010 · 90 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +10

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

Séverine Vermeire, Bruce E. Sands, Herbert Tilg et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 64 citations

Medicine, Clinical Sciences, Pharmacology +14

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial

Ivan Bunganič, E. А. Belousova, Limas Kupčinskas et al. · Journal of Crohn s and Colitis · 2010 · 61 citations · Full text

Pharmacy, Pharmacotherapy, Gastroenterology +12

Long‐term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)—results from the European phase 3 open‐label safety trial

Jan Tack, Juris Pokrotnieks, Gediminas Urbonas et al. · Neurogastroenterology & Motility · 2018 · 52 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14